Muscarine Toxicity Profile
Muscarine Toxicity Profile - Related Videos
01:25
Cholinergic Receptors: Muscarinic
0 Views •
2023
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
07:09
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
0 Views •
Cited by 7 •
2011
We describe procedures for repeated administration of inhibitors of muscarinic signaling to the levator auris longus (LAL) muscle of young adult mice and for subsequent immunostaining of its neuromuscular junctions (NMJs) in wholemounts. The LAL muscle has unique advantages for revealing in vivo pharmacological effects on NMJs.
01:20
Antiasthma Drugs: Muscarinic Receptor Antagonists
0 Views •
2024
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways. Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
09:01
A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans
0 Views •
Cited by 10 •
2019
A quantitative method has been developed to identify and predict the acute toxicity of chemicals by automatically analyzing the phenotypic profiling of Caenorhabditis elegans. This protocol describes how to treat worms with chemicals in a 384-well plate, capture videos, and quantify toxicological related phenotypes.
09:06
Growth Assays to Assess Polyglutamine Toxicity in Yeast
0 Views •
Cited by 3 •
2012
This manuscript describes three complementary protocols for assessing the toxicity of polyglutamine (polyQ)-expansion proteins in the yeast Saccharomyces cerevisiae. These protocols can easily be modified to monitor the toxicity of other misfolded proteins in yeast.
FAQs
Muscarine stimulates muscarinic acetylcholine receptors in peripheral parasympathetic pathways. Receptor activation increases glandular secretion, accounting for salivation, sweating, tearing, and bronchial secretions, while enhanced smooth-muscle activity contributes to abdominal cramping, vomiting, diarrhea, slowed heart rate, and visual changes. This receptor-level pattern links the observed symptoms to a coherent cholinergic mechanism.
Muscarine is not rapidly broken down by acetylcholinesterase, so its receptor stimulation can persist rather than ending immediately through enzymatic degradation. Continued activation sustains parasympathetic effects across secretory glands, smooth muscle, and cardiac pathways. This pharmacological property helps explain why clinicians must recognize the evolving cholinergic pattern and monitor affected patients after exposure.
A prominent combination of excessive secretions and gastrointestinal smooth-muscle activity is especially informative. Salivation, sweating, tearing, bronchial secretions, abdominal cramping, vomiting, and diarrhea occur alongside slowed heart rate and visual changes. Recognizing this coordinated muscarinic pattern helps pharmacologists and clinicians separate muscarine-related poisoning from mushroom toxicities that produce different clinical profiles.
Clinical effects usually develop soon after exposure, making the timing of symptom onset an important part of assessment. Early emergence of salivation, sweating, tearing, gastrointestinal symptoms, bronchial secretions, slowed heart rate, or visual changes supports consideration of muscarinic poisoning. The timing should be interpreted together with the overall cholinergic pattern rather than used alone.
Monitoring should follow the systems most directly affected by excessive muscarinic stimulation. Clinicians assess glandular secretions, breathing-related bronchial secretions, gastrointestinal activity, heart rate, and visual changes while watching how the pattern evolves. This approach supports recognition of a cholinergic syndrome, helps identify clinically important progression, and informs decisions about receptor-targeted treatment.
Treatment decisions are guided by the toxin's muscarinic receptor activity and the resulting cholinergic syndrome. When clinically indicated, receptor-targeted antimuscarinic therapy addresses the pharmacological source of excessive parasympathetic effects rather than treating each symptom independently. Recognition of the receptor pattern therefore connects bedside findings with a mechanism-based treatment strategy and appropriate monitoring.